A variety of antibodies have been developed against both PD-1 and PD-L1, including pembrolizumab (anti-PD1 mAb; FDA approved for HNSCC, melanoma and NSCLC) and nivolumab (anti-PD1; FDA approved for melanoma, NSCLC, and renal cell carcinoma). The gene discussed is CD274; the disease is melanoma.